Jennifer Samp, PHARMD, MS
AbbVie Inc.
1 North Waukegan Road
North Chicago,
IL
USA
60064
Papers:
2E-1
LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF DIFFERENT ANTIVIRAL TREATMENTS FOR CHRONIC GENOTYPE-1 HCV INFECTION IN GERMANY INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR
DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP
BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE